Then, to further validate the bioinformatic results that SPTBN1 expression was negatively associated with the expression of multiple immune modulator biomarkers in KIRC, we decide to detect expression of TNFSF9, an important immunotherapy checkpoint marker in KIRC, in tumor samples from high and low SPTBN1-expression KIRC groups using IHC staining (revised_Figure 7B). The gene discussed is SPTBN1; the disease is neoplasm.